US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

GeoVax Labs Inc

0.0267

0.0000

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:0.0267

Open:0.0267

Low:0.0267

Close:0.0267

Loading ...

Overview Company News Filings

GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update

GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting

GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater

GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress

GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025

GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations

GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital

GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum

GeoVax to Present Clinical Data at Upcoming April Industry Events

GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent

Geovax Labs Inc (GOVX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

GeoVax Reports 2024 Year-End Financial Results and Provides Business Update

GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

GeoVax to Present at the 37th Annual Roth Conference

Registration is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025

GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy

GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern

GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness

Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GOVXW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GOVXW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GOVXW\",,,,,undefined,":{"symbol":"GOVXW","market":"US","secType":"STK","nameCN":"GeoVax Labs Inc","latestPrice":0.0267,"timestamp":1752868800000,"preClose":0.0267,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"07-18 16:00:00 EDT","open":0.0267,"high":0.0267,"low":0.0267,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0267,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GOVXW\",,,,,undefined,":{"symbol":"GOVXW","floatShares":0,"roa":"-915.19%","roe":"-78814.57%","lyrEps":0,"shares":0,"dividePrice":0,"high":0.0267,"amplitude":0,"preClose":0.0267,"low":0.0267,"week52Low":0.0141,"pbRate":"0.00","psRate":"0.00","week52High":0.65,"institutionHeld":0,"latestPrice":0.0267,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0.0267,"prevYearClose":0.1001,"prevWeekClose":0.0201,"prevMonthClose":0.0251,"prevQuarterClose":0.0251,"fiveDayClose":0.0201,"twentyDayClose":0.0362,"sixtyDayClose":0.0302},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GOVXW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532839661","title":"GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2532839661","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532839661?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:00","pubTimestamp":1746129600,"startTime":"0","endTime":"0","summary":"COVID-19 vaccine program progressing with additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in second quarter of 2025. Clinical evaluation of GEO-MVA, vaccine candidate for protection against Mpox and Smallpox, expected to initiate in second half of 2025. \"Despite the recent and unexpected termination of our Project NextGen award by BARDA, our commitment to advancing GEO-CM04S1 remains unwavering. This next-generation, multi-antigen COVID-19 vaccine is highly differentiated and continues to show promise, particularly for the over 40 million immunocompromised individuals in the U.S. who remain vulnerable to current variants. Our ongoing Phase 2 trials, including studies in chronic lymphocytic leukemia patients and stem cell transplant recipients, are progressing well, with key data readouts anticipated in the first half of 2025,\" stated David Dodd, GeoVax's Chairman and CEO.GEO-CM04S1 continues to demonstrate potential as both a primary and boo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-reports-first-quarter-2025-200000871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVX","BK4588","BK4568","R","BK4022","BK4535","BK4548","BK4551","GOVXW","BK4232","BK4585","BNTX","BK4139"],"gpt_icon":0},{"id":"2531765670","title":"GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531765670","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531765670?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:00","pubTimestamp":1745942400,"startTime":"0","endTime":"0","summary":"Advancing Gene-Directed Prodrug Therapy: Data Presented at AACR Supports Gedeptin's Potential in Solid Tumors. ATLANTA, GA - April 29, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of new clinical data on its gene-directed enzyme prodrug therapy, Gedeptin, at the American Association for Cancer Research  Annual Meeting 2025, being held April 2530 in Chicago, IL.The presentation, titled \"Viral-Vectored, Gene-Directed Prodrug Therapy  in Needle-Accessible Solid Tumors,\" was delivered by J. Marc Pipas, M.D., Executive Medical Director, Oncology at GeoVax, during the Phase II Clinical Trials 1 Poster Session on April 29, 2025. The session drew significant interest from researchers and clinicians, underscoring the growing recognition of Gedeptin's therapeutic potential. The corresponding abstract was published in the AACR journal Cancer Research.\"These clini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-presents-gedeptin-r-clinical-160000847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","BK4139","LU2362540622.SGD","SD","BK4588","R","BK4107","BK4232","BK4195","PFS","BK4117","GOVXW","LU2362541273.HKD","GOVX","BK4213","LU1814569148.SGD","LU2517655374.HKD","BK4022","LU0154245673.USD","LU2362541513.USD","LU0107464264.USD","LU2517655291.USD","BK4585","BK4097","AFG","BK4211","OS","LU0154245756.USD","IT","LU2517655028.SGD","BK4134"],"gpt_icon":0},{"id":"2530094999","title":"GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater","url":"https://stock-news.laohu8.com/highlight/detail?id=2530094999","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530094999?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:02","pubTimestamp":1745524973,"startTime":"0","endTime":"0","summary":"GEO-MVA Advancing as the Leading U.S.-Developed Mpox Vaccine Candidate. ATLANTA, GA - April 24, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today responded to the recent detection of Clade I Mpox viral particles in wastewater samples in Greenville, North Carolina - the first such identification in the state. This finding, disclosed by the North Carolina Department of Health and Human Services , underscores the increasing threat posed by Clade I Mpox and the urgent need for expanded preparedness and Mpox vaccine availability.This development aligns with concerns raised by the Centers for Disease Control and Prevention , which continues to monitor Clade I Mpox - a more virulent strain associated with higher transmissibility and a greater case fatality rate than Clade II. Four confirmed Clade I Mpox cases have been reported in the U.S. to date - in California, Georgia, New Hampshire, and New","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-responds-detection-clade-mpox-200253222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVX","CARO","R","BK4022","CDC","BK4232","GOVXW"],"gpt_icon":0},{"id":"2530957512","title":"GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2530957512","media":"NewMediaWire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530957512?lang=en_us&edition=fundamental","pubTime":"2025-04-25 00:00","pubTimestamp":1745510400,"startTime":"0","endTime":"0","summary":"GEO-CM04S1 Demonstrates Durable T Cell and Antibody Responses in Healthy and Immunocompromised Populations. ATLANTA, GA - April 24, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today recapped the successful presentation of new clinical data on its multi-antigen SARS-CoV-2 vaccine candidate, GEO-CM04S1, delivered at the 25th Annual World Vaccine Congress in Washington, D.C.The presentation, titled \"Phase 2b Study Results That Evaluated and Compared GeoVax's Multi-Antigen Vaccine Candidate  to an Approved Vaccine Against COVID-19,\" was given by Don J. Diamond, Ph.D. on April 24, 2025. It highlighted results across several Phase 1 and 2 clinical trials, including studies involving healthy volunteers as well as immunocompromised patients such as stem cell transplant recipients and those with chronic lymphocytic leukemia .GEO-CM04S1, based on the synthetic Modified Vaccinia Ankara  vector platf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-highlights-strong-clinical-results-160000967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0225771236.USD","LU0868494617.USD","BK4581","BK4539","LU1894683348.USD","LU0321505868.SGD","GOVX","GOVXW","LU0225284248.USD","IE00BLSP4452.SGD","IE00BBT3K403.USD","LU0122379950.USD","LU1066051498.USD","BK4548","LU0058720904.USD","BK4022","BNTX","S","R","BK4007","BK4097","BK4535","LU0306806265.USD","IE00B19Z3581.USD","SG9999001176.SGD","LU1883839398.USD","BK4560","LU1057294990.SGD","BK4588","BK4232","BK4139","LU1023059063.AUD","BK4585","LU0170899867.USD","SG9999002224.SGD","LU0321505439.SGD","SG9999002232.USD","SG9999003800.SGD","IE000M9KFDE8.USD","SGXZ57979304.SGD","BK4551","BK4533","BK4592","BK4568","BK4599","SG9999011175.SGD","SG9999013999.USD","LU2286300806.USD","LU0234572021.USD","LU0985481810.HKD"],"gpt_icon":1},{"id":"2529625636","title":"GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529625636","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529625636?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:00","pubTimestamp":1745413200,"startTime":"0","endTime":"0","summary":"ATLANTA, GA - April 23, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-report-first-quarter-2025-130000003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVX","BK4535","R","BK4139","BK4588","BK4548","BK4551","BK4022","BK4568","BK4585","BNTX","BK4232","GOVXW","BK4583"],"gpt_icon":0},{"id":"2529588411","title":"GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2529588411","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529588411?lang=en_us&edition=fundamental","pubTime":"2025-04-22 21:00","pubTimestamp":1745326800,"startTime":"0","endTime":"0","summary":"Recognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities. ATLANTA, GA - April 22, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced the appointment of Senthil Ranganathan, Ph.D. as Vice President, Technical Development and CMC Operations. Dr. Ranganathan brings over 20 years of experience in biologics development to commercialization across vaccines, cell and gene therapies, monoclonal antibodies, and viral vector products.GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as  a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient po","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-appoints-dr-senthil-ranganathan-130000832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVXW","LU0170899867.USD","LU0971096721.USD","BK4022","LU0267386448.USD","R","BK4232","CMC","LU1363072403.SGD","GOVX","IE00BZ1G4Q59.USD","BK4006","IE00BHPRN162.USD","IE00BKVL7J92.USD","IE00B1BXHZ80.USD","LU0882574139.USD","LU0149725797.USD"],"gpt_icon":0},{"id":"2527241430","title":"GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2527241430","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527241430?lang=en_us&edition=fundamental","pubTime":"2025-04-16 22:15","pubTimestamp":1744812923,"startTime":"0","endTime":"0","summary":"D. Boral Capital lowered the firm’s price target on GeoVax Labs  to $14 from $18 and keeps a Buy rating on the shares. GeoVax has encountered a significant challenge following the termination of its BARDA-funded Phase 2b clinical trial for the GEO-CM04S1 COVID-19 vaccine, the firm says. This decision, made for the government’s convenience, halts a pivotal study that was set to evaluate GEO-CM04S1 against an approved mRNA vaccine in a 10,000-participant trial under Project NextGen. The abrupt termination raises concerns about the future trajectory of GeoVax’s vaccine development efforts and its financial implications, says D. Boral Capital. The firm has removed all BARDA revenues and stockpile awards that were in its model.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.GeoVax Labs price target lowered to $8.50 from $15 at Alliance Global Partners. GeoVax","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/geovax-labs-price-target-lowered-141523619.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-labs-price-target-lowered-141523619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVXW","GOVX"],"gpt_icon":0},{"id":"2527424145","title":"GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2527424145","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527424145?lang=en_us&edition=fundamental","pubTime":"2025-04-16 21:00","pubTimestamp":1744808400,"startTime":"0","endTime":"0","summary":"Company Reaffirms Commitment to Innovation in COVID-19, Oncology, and Biosecurity Amid Strategic Program Developments. ATLANTA, GA - April 16, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today addressed the termination of its Project NextGen  award by the Biomedical Advanced Research and Development Authority , effective April 11, 2025. The Company also provided a comprehensive business update across its core programs, including the next-generation COVID-19 vaccine , cancer immunotherapy , Mpox/smallpox vaccine , and advanced MVA manufacturing process.GeoVax expressed disappointment in the HHS/BARDA action but remains committed to the critical medical need addressed by GEO-CM04S1, particularly among the more than 40 million immunocompromised Americans - and over 400 million people globally - who remain inadequately protected by the current authorized COVID-19 vaccines. Thus far, clinical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-provides-barda-project-nextgen-130000111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","R","BK4535","BK4568","BK4585","BK4551","GOVX","NGCAU","BK4022","BK4232","BK4588","BNTX","BK4548","GOVXW"],"gpt_icon":0},{"id":"2527941465","title":"GeoVax to Present Clinical Data at Upcoming April Industry Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2527941465","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527941465?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:00","pubTimestamp":1744722000,"startTime":"0","endTime":"0","summary":"Data to be Presented on the Company's GEO-CM04S1 and Gedeptin Programs. ATLANTA, GA - April 15, 2025  - GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that members of its senior management team and other scientific representatives will participate in two upcoming industry events during April. Event details are as follows:. World Vaccine Congress, April 22-24, 2025, Washington, DC. Phase 2b Study Results That Evaluated and Compared GeoVax's Multi-Antigen, Vaccine Candidate  to an Approved Vaccine Against COVID-19. Don J. Diamond, PhD, Director, Division of Vaccine Research & Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center. Viral-Vectored, Gene-Directed Prodrug Therapy  in Needle-Accessible Solid Tumors","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-present-clinical-data-upcoming-130000897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","GOVXW","BK4232","BK4568","BNTX","BK4585","BK4551","BK4548","BK4588","BK4022","BK4139","R","GOVX","BK4583"],"gpt_icon":0},{"id":"2526358364","title":"GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2526358364","media":"NewMediaWire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526358364?lang=en_us&edition=fundamental","pubTime":"2025-04-09 21:00","pubTimestamp":1744203600,"startTime":"0","endTime":"0","summary":"Continues to Strengthen Its Pandemic Preparedness and Biodefense Vaccine Portfolio. ATLANTA, GA - April 9, 2025  - GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office  has issued a Notice of Allowance for Patent Application No. 18/394,555 titled \"Replication-Deficient Modified Vaccinia Ankara  Expressing Marburg Virus Glycoprotein  and Matrix Protein .\" The allowed claims generally cover prevention of Marburg virus infection utilizing GeoVax's proprietary MVA-based Marburg vaccine.Dodd continued, \"Our focus extends beyond individual product candidateswe are building a broad, durable defense platform against hemorrhagic fever viruses. We believe this strategy, supported by compelling preclinical data and prioritized by global health authorities, positions GeoVax to play a central role in pandemic preparedness and biodefense.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-receives-uspto-notice-allowance-130000606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4585","BK4568","BK4022","BK4588","BK4535","BNTX","R","GOVX","BK4139","GOVXW","BK4232","VLP","GP","BK4149","BK4548"],"gpt_icon":0},{"id":"2522445519","title":"Geovax Labs Inc (GOVX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2522445519","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522445519?lang=en_us&edition=fundamental","pubTime":"2025-03-28 15:03","pubTimestamp":1743145393,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Geovax Labs Inc  received a significant Project NextGen Award valued at almost $400 million to support their next-generation COVID-19 vaccine, CMO4S1.The company has completed CGMP product and quality release for their Mpox and smallpox vaccine candidate, GOMVA, with plans for clinical evaluation in the second half of the year.The company's cash balance decreased to $5.5 million at the end of 2024, reflecting significant cash usage in operating activities.There is uncertainty regarding the ability to sell the Mpox vaccine without clinical testing, despite the urgent global need.GuruFocus has detected 2 Warning Signs with GOVX.Q: Given the urgency of the Mpox threat, could GeoVax Labs potentially sell products without clinical testing, considering the testing is supposed to start around the end of 2025?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-labs-inc-govx-q4-070313586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVX","GOVXW"],"gpt_icon":0},{"id":"2522853197","title":"GeoVax Reports 2024 Year-End Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522853197","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522853197?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:00","pubTimestamp":1743105600,"startTime":"0","endTime":"0","summary":"GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed. Additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in first half of 2025. Clinical evaluation of GEO-MVA, vaccine candidate for protection against Mpox and Smallpox, expected to begin in second half of 2025. Planning underway for Phase 2 clinical trial of Gedeptin as treatment for first recurrent head and neck cancer in combination with immune checkpoint inhibitor. \"In parallel, we are advancing our manufacturing capabilities to address emerging threats to public health and U.S. national security. The need for these measures is critical and urgent, as evidenced by the recent Mpox public health emergency declaration by the World Health Organization. GeoVax remains committed to bolstering global preparedness through GEO-MVA, our vaccine candidate in development for protection against Mpox and s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-reports-2024-end-financial-200000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","GOVX","BK4568","BK4139","BK4588","GOVXW","R","BK4535","BK4551","BNTX","BK4232","BK4585","BK4548","BK4583"],"gpt_icon":1},{"id":"2521740024","title":"GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2521740024","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521740024?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"ATLANTA, GA - March 24, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 3,435,115 shares of its common stock  and warrants to purchase up to an aggregate of 3,435,115 shares of common stock in a registered direct offering  at a combined purchase price of $1.31 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $1.31 per share, will be exercisable upon shareholder approval and will expire 5 years from shareholder approval.GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tum","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-labs-announces-4-5-120000971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","BK4568","IE00BGHQF748.EUR","TQQQ","BK4588","GOVXW","BK4022","R","BK4232","IE00B3QW5Z07.USD","BK4585","BK4139","QID","MNQmain","BK4548","NQmain","IE00B64PRP62.GBP","LU2095319765.USD","NVIW.SI","USAW.SI","BK4535","BK4551","BK4112","QQQ","BNTX","USJW.SI","IE00BKPKM429.USD","BK4583","SQQQ","QLD","LU2210149790.SGD","GOVX","TSYW.SI","NDAQ",".IXIC","LU2210150020.SGD"],"gpt_icon":0},{"id":"2520211635","title":"GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520211635","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520211635?lang=en_us&edition=fundamental","pubTime":"2025-03-17 21:00","pubTimestamp":1742216400,"startTime":"0","endTime":"0","summary":"ATLANTA, GA - March 17, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report 2024 financial results on Thursday, March 27, 2025, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-report-fourth-quarter-full-130000343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["R","BK4232","BK4568","BK4535","BK4585","GOVX","BK4139","BK4588","GOVXW","BK4022","BNTX","BK4583","BK4548","BK4551"],"gpt_icon":0},{"id":"2518741807","title":"GeoVax to Present at the 37th Annual Roth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2518741807","media":"NewMediaWire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518741807?lang=en_us&edition=fundamental","pubTime":"2025-03-11 21:00","pubTimestamp":1741698000,"startTime":"0","endTime":"0","summary":"ATLANTA, GA - March 11, 2025  - GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 37th Annual Roth Conference, taking place in Dana Point, CA on March 16-18, 2025. Mr. Dodd's presentation will be in the form of a fireside chat moderated by Roth Managing Director, Senior Research Analyst Jonathan Aschoff, PhD.The Company will also host in-person investor meetings. Institutional investors wishing to attend the conference and schedule meetings with GeoVax leadership should contact their Roth MKM representative.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-present-37th-annual-roth-130000032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4139","BK4585","BK4551","BK4588","GOVX","R","BK4232","GOVXW","BK4022","BK4535","BK4568","BNTX"],"gpt_icon":0},{"id":"2516674780","title":"Registration is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event MPOX 2025: Navigating the Global Public Health Emergency Featuring GeoVax CEO On March 6, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674780","media":"NewMediaWire","labels":["conferences","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674780?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":"Mpox remains a global public health crisis in 2025, with Clade 1b exhibiting higher transmissibility and severity than Clade 2.The Democratic Republic of the Congo  is the epicenter, with over 60,000 suspected cases and 1,300 deaths in 2024 alone.GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as  a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/registration-now-open-tribe-publics-140000126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4535","BK4548","BNTX","GOVXW","BK4568","R","BK4232","BK4551","GOVX","BK4022","BK4588","BK4139"],"gpt_icon":0},{"id":"2516631604","title":"GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631604","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516631604?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:00","pubTimestamp":1741010400,"startTime":"0","endTime":"0","summary":"ATLANTA, GA - March 3, 2025  - GeoVax Labs, Inc. , a leader in developing vaccines and immunotherapies for infectious diseases and cancer, underscores the strategic importance of its Modified Vaccinia Ankara  vaccine platform in helping to bolster U.S. biodefense capabilities. Efforts in MVA vaccine design and manufacturing improvements align with key recommendations from the recent \"Bolstering U.S. Biodefense: Recommendations For The New Administration\" report, published by the Janne E. Nolan Center on Strategic Weapons at the Council on Strategic Risks, a respected think tank specializing in national security and biodefense policy. The report emphasizes the need for robust, diversified medical countermeasures to protect national and global security.The \"Bolstering U.S. Biodefense\" report highlights the urgency of strengthening U.S. preparedness against biological threats, including deliberate attacks, emerging infectious diseases, and supply chain vulnerabilities. GeoVax's efforts to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-highlights-critical-role-mva-140000823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4596","BK4595","BK4516","BK4551","BK4022","BK4232","GOVXW","HHS","BNTX","BK4585","BK4139","STRK","GOVX","R","BK4535","BK4023","BK4009","BK4548","BK4588","BK4600","BK4568"],"gpt_icon":1},{"id":"2514331728","title":"GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern","url":"https://stock-news.laohu8.com/highlight/detail?id=2514331728","media":"NewMediaWire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514331728?lang=en_us&edition=fundamental","pubTime":"2025-02-28 03:22","pubTimestamp":1740684136,"startTime":"0","endTime":"0","summary":"GeoVax Advancing GEO-MVA Vaccine Candidate to Bolster Global Supply Options. ATLANTA, GA - February 27, 2025  - GeoVax Labs, Inc.  commented on today's statement from The World Health Organization  concerning Mpox. In its statement the WHO reaffirmed the severity of the ongoing Mpox epidemic, issuing its third declaration within six months of Mpox as a Public Health Emergency of International Concern . This follows the initial declaration on August 14, 2024, and the second on November 22, 2024, underscoring the persistent and escalating nature of the outbreak.GEO-MVA, in conjunction with the GeoVax development program of implementing an advanced manufacturing process for MVA vaccines, may offer several key advantages to complement and potentially strengthen the global Mpox response:. Expanded manufacturing capacity at lower cost - The advanced MVA manufacturing process is directed towards establishing a higher yield, increased production capability with lower production costs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-response-whos-third-declaration-192216075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVXW","GOVX","BK4548","BK4585","BK4535","BK4139","BNTX","R","BK4551","BK4232","BK4022","BK4568","BK4588"],"gpt_icon":1},{"id":"2513724718","title":"GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness","url":"https://stock-news.laohu8.com/highlight/detail?id=2513724718","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513724718?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:00","pubTimestamp":1740405600,"startTime":"0","endTime":"0","summary":"Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax's MVA-Based GEO-CM04S1 for Enhanced Protection, Particularly for Immunocompromised Populations. ATLANTA, GA - February 24, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company specializing in immunotherapies and vaccines, today reaffirms the critical role that mRNA vaccines have played in combating the COVID-19 pandemic and highlights the growing recognition of the need for complementary vaccine platforms, particularly for immunocompromised patients and those requiring broader, more durable immunity.The rapid development and deployment of mRNA vaccines were pivotal in mitigating the initial impact of the pandemic, offering a timely and effective response. However, the scientific literature continues to underscore the importance of a diversified vaccine strategy directed towards enhanced durability and expanded protection against variants for populations that may not mount a sufficiently strong imm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-highlights-role-mva-based-140000814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","S","BNTX","BK4548","BK4583","LU2286300806.USD","GOVXW","R","BK4232","BK4009","BK4561","BK4560","BK4568","BK4535","BK4551","BK4539","BK4585","HHS","GOVX","BK4097","BK4139","BK4588"],"gpt_icon":0},{"id":"2512100049","title":"Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification","url":"https://stock-news.laohu8.com/highlight/detail?id=2512100049","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512100049?lang=en_us&edition=fundamental","pubTime":"2025-02-19 22:00","pubTimestamp":1739973600,"startTime":"0","endTime":"0","summary":"GeoVax Advances GEO-MVA to Strengthen U.S. and Global Readiness. ATLANTA, GA - February 19, 2025  - The confirmation of a fourth case of Clade 1 Mpox in New York underscores the urgent need for a stronger and more diversified vaccine supply chain. GeoVax Labs, Inc. , a leader in developing vaccines and immunotherapies for infectious diseases and cancer, is calling for immediate action to expand vaccine production and ensure timely distribution.In response to these pressing concerns, GeoVax is advancing development of GEO-MVA, an alternative MVA based vaccine in the fight against Mpox. GeoVax is also further addressing vaccine availability with plans to transition manufacturing of GEO-MVA, once authorized, to an advanced MVA manufacturing platform with the potential to offer significant advantages over the currently utilized Chicken Embryo Fibroblast  manufacturing platform, a complicated manufacturing process highly dependent on the availability of Specific Pathogen Free  chicken eggs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mpox-clade-1-u-highlights-140000755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4139","BK4022","BK4548","BNTX","GOVXW","BK4588","CEF","GOVX","BK4583","BK4568","BK4535","BK4232","BK4585","R"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GOVXW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-08-03","symbol":"GOVXW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1659499200000,"reportTimeType":"post","actualEps":null},{"date":"2022-04-27","symbol":"GOVXW","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1651089600000,"name":null,"time":"Post Market","dateTimestamp":1651032000000,"actualEps":null},{"date":"2022-03-09","symbol":"GOVXW","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1646859600000,"name":null,"time":"Post Market","dateTimestamp":1646802000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GOVXW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GOVXW\",market:\"US\",delay:false,,,undefined,":{}}}